OncoCyte (NASDAQ:OCX) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX) in a research report issued on Wednesday. The firm set a “sell” rating on the stock.

Other equities research analysts have also recently issued reports about the stock. Benchmark reiterated a “speculative buy” rating and issued a $5.00 price target on shares of OncoCyte in a research report on Monday, April 15th. Stephens reiterated an “equal weight” rating and issued a $4.00 price target on shares of OncoCyte in a research report on Wednesday, April 17th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $4.06.

OncoCyte Trading Down 0.8 %

Shares of OncoCyte stock opened at $2.44 on Wednesday. The company’s 50-day moving average price is $2.91 and its two-hundred day moving average price is $3.04. OncoCyte has a 52 week low of $2.08 and a 52 week high of $6.20.

Insider Buying and Selling

In other OncoCyte news, major shareholder Broadwood Partners, L.P. bought 2,420,000 shares of the stock in a transaction on Thursday, April 11th. The shares were bought at an average price of $2.92 per share, with a total value of $7,066,400.00. Following the purchase, the insider now directly owns 4,929,066 shares in the company, valued at approximately $14,392,872.72. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other OncoCyte news, major shareholder Broadwood Partners, L.P. bought 2,420,000 shares of the stock in a transaction on Thursday, April 11th. The shares were bought at an average price of $2.92 per share, with a total value of $7,066,400.00. Following the purchase, the insider now directly owns 4,929,066 shares in the company, valued at approximately $14,392,872.72. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Andrew Arno bought 33,898 shares of the stock in a transaction on Thursday, April 11th. The shares were acquired at an average cost of $2.95 per share, for a total transaction of $99,999.10. Following the purchase, the director now owns 69,054 shares in the company, valued at $203,709.30. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 2,457,288 shares of company stock valued at $7,176,400. 1.94% of the stock is owned by corporate insiders.

About OncoCyte

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.